04/03/2009 11:36

CTL Writes Book Chapter on Validating Reference Samples for Use in Cell-Based Assays

In a new book on cell-based assays, CTL discusses key considerations in validating an ELISPOT assay.

Cellular Technology Limited has contributed a key chapter to the book, Validation of Cell-Based Assays in the GLP Setting: A Practical Guide. This text is one of the latest offerings by Research and Markets, a leading source for international market research and market data.

This book describes the development, optimization and validation of various cell-based assays, such as cytokine ELISPOT and ELISA assays, for which validation procedures have been developed. In addition, it discusses the validation of these assays for select targets using step-by-step instructions. Chapter 9 ("Validating reference samples for comparison in a regulated ELISPOT assay") was written by CTL personnel Magdalena Tary-Lehmann, Christina D. Hamm, and Paul V. Lehmann. In this chapter, they discuss the utility and performance of the ELISPOT method, as well as key considerations in validating such assays.

Validation of Cell-based Assays in the GLP Setting is an invaluable reference source for pharmaceutical companies and biotechnology firms that need to evaluate drug targets derived from genomics and proteomics. It is also a useful reference for companies that use cell-based technologies for biomarker discovery and development.

In addition, the potential of biomarkers to facilitate the development of effective and safe drugs is being recognized as an integral part of all phases of drug development, and cell-based technologies are a critical part of biomarker discovery and development.

 

For more information visit www.researchandmarkets.com/reports/c89231.

News archive

Featured products

CTL QC Sets™

CTL’s Reference Sample QC Sets™ offer outstanding inter-assay control. Use CTL's QC Sets™ not only for validation and protocol setup purposes, but also as internal controls for clinical trials...

CTL QC Sets™

CTL Contract Services


Establishing new assays typically requires a major investment of effort and capital. Are your manpower levels stretched thin? Would you like to save both time and money? Let CTL’s team of experts handle the details for you.

CTL has been providing contract research services to government laboratories, major pharmaceutical companies, biotechnology companies, and academic institutions for nearly a decade. Our company has been recognized by the Cancer Vaccine Consortium as its ELISPOT reference laboratory and has been awarded a contract by the U.S. National Institutes of Health (NIH) to validate the ELISPOT assay for pre-clinical and clinical trials.

Thanks to its in-house expertise and rigorous procedures, CTL can conduct all assays in a GLP-compliant manner— whether to validate the test methods, to satisfy FDA requirements, or simply evaluating specimens for scientific significance. CTL also provides high-throughput data acquisition, evaluation, and quality control, allowing us to process large assays within a relatively short amount of time. For new clients, CTL can schedule an initial telephone conference to discuss how CTL products and services can assist the clients in achieving their goals.

 

Contract Laboratory Services


ELISPOT Testing

ELISA Testing

Flow Cytometry Testing

Specimen Processing and Cryopreservation

Sample Management